Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of the groundbreaking WEB™ Aneurysm Embolization System. Since its introduction, the WEB device has transformed the treatment of wide-neck bifurcation aneurysms, offering physicians and patients a clinically proven, single-device solution – One and Done – with proven simplicity, proven safety and durability, proven for ruptured aneurysms* and proven innovation2-9.
The WEB device was commercially launched in October 2010 after receiving its CE (Conformité Européenne) Mark in Europe. The first implant was performed by Prof. Joachim Klisch in Germany, paving the way for a new era in aneurysm treatment.
The WEB device has proven clinical data, supported by seven global Good Clinical Practice (GCP) studies2-8 and over 200 peer-reviewed publications. Over the past 15 years, this revolutionary technology has changed the paradigm for aneurysm treatment, providing a safe, effective alternative to traditional methods.
Carsten Schroeder, President and CEO of Terumo Neuro, commented on this significant milestone: “The WEB device has set a new standard in aneurysm treatment and has been instrumental in our mission to drive game-changing impact in neurovascular care. With 15 years of proven clinical success, WEB continues to advance patient outcomes, reducing the need for multiple devices and lengthy procedures. As we celebrate this achievement, we remain committed to innovating alongside leading physicians worldwide to shape the future of neurovascular care.”
Transforming Aneurysm Treatment with the WEB Device
The WEB device is the world’s first intrasaccular flow disruptor, designed to treat brain aneurysms from inside the aneurysm sac. Unlike traditional treatments for wide-neck bifurcation aneurysms that require stents and coils, this device minimizes the need for dual antiplatelet therapy, simplifying procedures and enhancing patient safety, with a single device. Key milestones and clinical highlights of Terumo Neuro’s WEB embolization system include:
- Unparalleled Clinical Data: The WEB device has been studied in over 600 patients across seven GCP trials, accumulating more than 1,464 patient-years with zero recorded rebleeds in a WEB device-treated aneurysm.2-8
- Proven Long-Term Safety & Durability: The five-year follow-up data from the WEB-IT, WEBCAST and WEBCAST 2 trials reaffirmed the WEB system’s sustained efficacy and safety, including 0% device-related morbidity and mortality.7,8
- Expanding Treatment Options: The introduction of the WEB 17 system, a lower profile system to treat smaller aneurysms, has further refined aneurysm treatment providing physicians with greater flexibility and precision for a wider range of cases.
The WEB device’s continued evolution underscores Terumo Neuro’s dedication to advancing neurovascular technology. With more than 25,000 patients treated with the WEB device worldwide, this intrasaccular device remains the trusted choice for physicians seeking a reliable, single-device solution for wide-neck bifurcation aneurysms.
